bioAffinity TechnologiesBIAF
BIAF
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 57
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
6% more funds holding
Funds holding: 16 [Q4 2024] → 17 (+1) [Q1 2025]
0.15% less ownership
Funds ownership: 3.44% [Q4 2024] → 3.29% (-0.15%) [Q1 2025]
73% less capital invested
Capital invested by funds: $497K [Q4 2024] → $132K (-$365K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for BIAF.
Financial journalist opinion
Based on 4 articles about BIAF published over the past 30 days
Neutral
Business Wire
4 days ago
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board
SAN ANTONIO--(BUSINESS WIRE)-- #ALA--bioAffinity CEO Maria Zannes joins the American Lung Association in Texas' Leadership Board of to advance prevention and treatment of lung disease.
Neutral
Business Wire
2 weeks ago
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces new patent for method of selectively killing cancer by targeting two specific receptors on the cell membrane.
Negative
Zacks Investment Research
3 weeks ago
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
Neutral
Business Wire
3 weeks ago
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Pulmonologist Gordon Downie, MD, PhD, joins bioAffinity Technologies as Chief Medical Officer.
Neutral
Business Wire
1 month ago
bioAffinity Technologies Reports First Quarter 2025 Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports first-quarter 2025 results.
Neutral
Business Wire
1 month ago
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A newly released white paper shares four real-world cases where bioAffinity's CyPath® Lung played a pivotal role in guiding clinical decisions.
Neutral
PRNewsWire
1 month ago
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
JERSEY CITY, N.J. , May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.
Neutral
Business Wire
1 month ago
bioAffinity Technologies Announces Closing of $3.25 Million Offering
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.
Neutral
PRNewsWire
1 month ago
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
JERSEY CITY, N.J. , May 6, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and other estimated expenses payable by the company.
Neutral
Business Wire
1 month ago
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.
Charts implemented using Lightweight Charts™